Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PRTA 
Prothena Corporation plc (PRTA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/28/2025: PRTA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $16.5
1 Year Target Price $16.5
| 5 | Strong Buy |
| 3 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 15.97% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 567.37M USD | Price to earnings Ratio - | 1Y Target Price 16.5 |
Price to earnings Ratio - | 1Y Target Price 16.5 | ||
Volume (30-day avg) 10 | Beta -0.12 | 52 Weeks Range 4.32 - 18.77 | Updated Date 10/28/2025 |
52 Weeks Range 4.32 - 18.77 | Updated Date 10/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.62 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1176.63% |
Management Effectiveness
Return on Assets (TTM) -29.8% | Return on Equity (TTM) -66.85% |
Valuation
Trailing PE - | Forward PE 33.9 | Enterprise Value 176107520 | Price to Sales(TTM) 54.87 |
Enterprise Value 176107520 | Price to Sales(TTM) 54.87 | ||
Enterprise Value to Revenue 17.03 | Enterprise Value to EBITDA -3.58 | Shares Outstanding 53829928 | Shares Floating 40091494 |
Shares Outstanding 53829928 | Shares Floating 40091494 | ||
Percent Insiders 19.06 | Percent Institutions 79.18 |
Upturn AI SWOT
Prothena Corporation plc
Company Overview
History and Background
Prothena Corporation plc is a late-stage clinical biotechnology company focused on the discovery and development of novel therapies to treat diseases with high unmet need, including neurodegenerative diseases. Founded in 2012 as a spin-off from Elan Corporation.
Core Business Areas
- Neurodegenerative Disease Therapeutics: Prothena focuses on developing therapies for diseases like Alzheimer's, Parkinson's, and ATTR amyloidosis.
Leadership and Structure
Gene Kinney is the President and CEO. The company has a board of directors and operates with a functional organizational structure focused on research and development.
Top Products and Market Share
Key Offerings
- PRX012 (Alzheimer's Disease): An investigational antibody designed to target aggregated amyloid beta. Currently in clinical trials. Market share is currently 0% as it is not approved. Competitors include Biogen (BIIB), Eisai (ESAI), and Eli Lilly (LLY).
- Birtamimab (ATTR Amyloidosis): An investigational antibody designed to neutralize soluble aggregates of misfolded transthyretin (TTR) protein. Failed Phase 3, partnered with Neurimmune. Market Share is currently 0% as it is not approved.
- PRX005 (Parkinson's Disease): An investigational antibody targeting alpha-synuclein. Licensed to Bristol Myers Squibb (BMY). Market Share is currently 0% as it is not approved. Competitors include Biogen (BIIB) and UCB (UCB).
Market Dynamics
Industry Overview
The biotechnology industry is experiencing rapid growth, driven by technological advancements and an aging global population. The neurodegenerative disease therapeutics market is particularly large and underserved.
Positioning
Prothena is positioned as an innovative, late-stage clinical biotechnology company focused on developing therapies for neurodegenerative diseases. They focus on first-in-class approaches and novel targets. Competitors are much larger and have already approved products.
Total Addressable Market (TAM)
The neurodegenerative disease market TAM is estimated to be in the tens of billions of dollars. Prothena is positioning itself to capture a portion of this market with its pipeline products, despite significant risks associated with clinical trials and regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel therapeutic targets
- Late-stage clinical pipeline
- Strong scientific expertise
- Partnerships with major pharmaceutical companies
Weaknesses
- High cash burn rate
- Clinical trial risk
- Dependence on partnered programs
- Limited revenue streams
Opportunities
- Regulatory approval of key pipeline assets
- Expansion of pipeline through new targets and technologies
- Strategic acquisitions or partnerships
- Growing demand for neurodegenerative disease therapies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- BIIB
- ESAI
- LLY
- ABBV
- SNY
Competitive Landscape
Prothena faces intense competition from larger pharmaceutical companies with more resources and approved products. Prothena differentiates itself through novel targets and approaches.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by advancement of pipeline programs and partnership agreements.
Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approvals. Analyst projections are highly variable due to the inherent risk in biotechnology.
Recent Initiatives: Focusing on advancing PRX012, PRX005, and strategic collaborations.
Summary
Prothena is a high-risk, high-reward biotechnology company focused on neurodegenerative diseases. Its success hinges on the outcome of its clinical trials and the ability to secure partnerships. While the company has strong scientific expertise and a promising pipeline, it faces significant financial and regulatory challenges. The company needs to monitor regulatory hurdles and focus on clinical trials to drive future growth. It also needs to manage its cash burn as it is not yet profitable.
Similar Stocks
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is an estimate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Prothena Corporation plc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2012-12-21 | President, CEO & Director Dr. Gene G. Kinney Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 163 | Website https://www.prothena.com |
Full time employees 163 | Website https://www.prothena.com | ||
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.